Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Haldol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Haloperidol 10 mg Tablets (Cord Laboratories) |
| 2 | ACTIVE_COMPARATOR | Haldol 10 mg Tablets (McNeil Pharmaceuticals) |
| Name | Type | Description |
|---|---|---|
| Haloperidol 10 mg Tablets (Cord Laboratories) | DRUG | - |
| Haldol 10 mg Tablets (McNeil Pharmaceuticals) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Haldol is a small molecule used for psychosis. It is being developed by Novartis AG for this psychiatric condition. The drug is currently in Phase 1 clinical development, meaning it is still investigational and has not been approved for use.
Haldol is developed by Novartis AG, a company traded under the ticker NVS. The drug is a small molecule being studied for the treatment of psychosis. It is currently in Phase 1 clinical development.
Haldol is in Phase 1 clinical development. It is an investigational drug being studied for psychosis. The drug has not been approved, and its safety and efficacy are still being evaluated in early-stage clinical trials.
Haldol has one completed clinical trial, NCT00946491, which was a Phase 1 study titled "To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers." The trial enrolled 30 healthy male volunteers aged 35 years and older.
Haldol is the brand name for the drug haloperidol. The clinical trial NCT00946491 compared generic haloperidol tablets to Haldol to demonstrate bioequivalency. Both refer to the same active pharmaceutical ingredient.